artificial blood

(redirected from Blood substitutes)
Also found in: Dictionary, Thesaurus, Legal, Encyclopedia, Wikipedia.

artificial blood

artificial blood

Artificial oxygen carrier Transfusion medicine A synthetic or semisynthetic substance used to transport O2; usually a blood loss of 20-25% is well tolerated and crystalloids–eg, dextrose, are adequate to raise the blood volume to acceptable levels
References in periodicals archive ?
Under the Phase III protocol cleared by the FDA, Northfield has infused surgical patients with up to six units of PolyHeme, Northfield's proprietary blood substitute.
In addition, the candidates vow to: -- Find a major pharmaceutical partner for Northfield to provide cash and experienced management to get PolyHeme approved by the FDA; -- Ask Northfield to partner with companies to extend possible applications of PolyHeme as a transport delivery mechanism for other drugs; -- Work with the Department of Defense and the Homeland Security Agency to explore the possibility of stockpiling PolyHeme as a safe, effective blood substitute for emergencies; -- Gain representation on Northfield's board as independent directors; and -- Keep investors informed of Northfield news.
Still, he points out, progress has been made in the quest for the perfect blood substitute.
The lab- developed haemoglobin is a safe and portable blood substitute.
This will be an excellent opportunity to share our novel approach to the quest for a blood substitute which is employed in HemoTech(TM).
HemoBioTech has a worldwide exclusive license to HemoTech, which is being developed as a blood substitute.
Oxygen carrier solutions, or blood substitutes, offer advantages over the use of erythrocytes in transfusion medicine (1).
Researchers at the School of Medicine also are testing promising new blood substitutes that carry oxygen just like red blood cells.
Although first generation blood substitutes have failed due to toxicity problems, including a most recent FDA denial for the product PolyHeme from Northfield Laboratories, the blood substitute technology of HemoBioTech, HemoTech, has the potential to be the first viable blood substitute.
Hemoglobin has been a favorite starting point for developers of blood substitutes.
Chang invited experts in their fields to provide descriptions and discussions about blood substitutes in Phase II and III clinical trials as well as discussions about future generations of blood substitutes.
The Company believes that HemoTech, due to its novel structure, may possess properties that diminish the intrinsic toxicities that have plagued other attempts at developing blood substitutes, based upon pre-clinical and initial human clinical trials undertaken outside the U.